FINWIRES · TerminalLIVE
FINWIRES

リナマーは2026年の見通しを維持したが、株価は水曜日に12%以上下落した。

By

-- 昨日、株価が12%以上下落したリナマー(LNR.TO)は、水曜日の市場取引終了後、最近のセクション232関税の改正を受けて、2026年度通期業績見通しを維持すると発表した。 同社は、改定後のセクション232関税に関して、モビリティ事業への影響はないと見込んでいる。これは、対象製品が関税免除対象であるか、関税関連費用が顧客によって負担されているためである。 一方、産業事業の一部の製品は、以前のセクション232関税制度と比較して「より顕著な影響」を受けており、「その影響範囲を積極的に評価している」としている。 声明によると、リナマー社は「セクション232関税の最近の変更について徹底的な見直しを行い、調達、価格設定、その他の手段の調整を含む様々な緩和策を講じている」とのことです。また、「この評価は現在も進行中ですが、リナマー社は確立されたプロセスと関税環境への対応経験に基づき、効果的に対応できる体制を整えています。詳細については、2026年5月6日に予定されている2026年第1四半期決算発表時にご説明いたします」と述べています。 さらに、セクション232関税の改正に関する初期評価に基づき、2026年の売上高成長率、調整後EPS成長率、フリーキャッシュフローの予測を維持するとしています。 リナマー社のリンダ・ハセンフラッツ会長は、「今日のダイナミックな地政学的環境において、長期的なファンダメンタルズと原則に引き続き注力することがこれまで以上に重要です。これは企業にとっても政府にとっても同様です。米国は当社にとって最大の貿易相手国であり、両国は深く結びついており、互いに極めて重要な関係にあります」と述べています。 232条関税とUSMCAの継続について合意をまとめれば、残りのことはビジネスが解決してくれるだろう。

Related Articles

Equities

Canada's Retail Sales Momentum May Fade Later in The Year, Says National Bank

Statistics Canada's advance estimate points to a 0.6% month-over-month nominal increase in March retail sales, said National Bank of Canada after Friday's data.Given the surge in gasoline prices that occurred in the month, this figure heavily reflects higher prices at the pump. As a result, in real terms, retail sales could register a contraction in the final month of Q1, noted the bank.Nonetheless, for the quarter, information received to date indicates that real retail sales could grow at a 4.7% annualized pace, following a 2.0% decline in the previous quarter -- marking the strongest quarterly performance since Q4 2024, stated National Bank.This is all the more impressive as it is occurring against a backdrop of demographic contraction, pointed out the bank.Indeed, the most recent figures from StatsCan indicate that the country's population declined for a second consecutive quarter -- an unprecedented development.As a result, real retail spending per capita is tracking a 5.2% increase in Q1, a rebound from the sluggish prints seen in 2025. Still, National Bank thinks that this momentum could fade fast as the year progresses.As a result of the conflict in the Middle East, households will face an erosion in purchasing power in the coming months. This, combined with a mortgage interest-payment shock and a still fragile labor market, could weigh on discretionary spending going forward, according to the bank.

$$CXY
Australia

Cinemark Likely to Benefit From Release Slate, Wedbush Says

Cinemark (CNK) is set to benefit from a more consistent release slate over the next several quarters and further market share gains, Wedbush said in a Monday note."The summer slate, especially in Q3, is shaping up very nicely," the report said.The note said theater investments, including laser projectors, premium seats and screens, IMAX expansion, and strategic pricing could drive market share gains. It also pointed to other benefits such as new builds and returning cash to shareholders.For its Q1 results due May 1, Wedbush expects Cinemark to post Q1 revenue of $638 million, against consensus of $629 million, and a loss of $0.03 per share, against consensus of $0.16 loss.Wedbush kept its outperform rating and a $37 price target.Price: $29.40, Change: $+0.92, Percent Change: +3.23%

$CNK
Asia Markets

Swiss Market Index Closes Little Changed; Santhera Shares Jump

The blue-chip Swiss Market Index was down 0.03% on Monday's close, as investors gear up for a busy week of corporate updates, economic data prints and key monetary policy decisions.Santhera Pharmaceuticals (SANN.SW) secured a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use to expand the approval of its Duchenne muscular dystrophy drug Agamree to include the treatment of children who are at least two years old. The drug is currently approved for use on patients aged four and above. The Swiss specialty pharmaceutical company's shares gained 8.38% at closing.Meanwhile, RBC Capital Markets reiterated its outperform rating on Lonza Group (LONN.SW), with a price target of 670 francs, amid expectations that the Swiss pharmaceutical manufacturer's upcoming first-quarter update would be "uneventful." At the end of the trading day, the stock was up 1.83%."We do not see the Q1 qualitative update on 8 May to be a major catalyst for the stock now that Vacaville-specific commentary will no longer be provided, and any further weakness in Specialized Modalities should not be a surprise. We have also taken the opportunity to refresh and add to our commercial product (Enflonsia) and pipeline trackers. There has been some clinical progress, but consensus forecasts have been pushed out a little (aggregate peak sales estimates are unchanged)," the research firm said, noting that it views Lonza as an "attractive and undervalued compounding investment story."The local economic news calendar was empty for the day, while the release of the Swiss KOF Economic Barometer and the UBS & CFA Society Switzerland's economic sentiment index for April, as well as the country's March retail sales figures are on the agenda over the coming days. Market watchers are also awaiting the rate decisions of the US Federal Reserve, the European Central Bank, and the Bank of England.

$^SSMI$LONN.SW$SANN.SW